Prognostic factors in ductal carcinoma in situ

被引:11
作者
Lebeau A. [1 ,2 ]
机构
[1] Institut für Pathologie, Universitäsklinikum Hamburg-Eppendorf
[2] Institut für Pathologie, Universitätsklinikum Hamburg-Eppendorf, 20246 Hamburg
来源
Der Pathologe | 2006年 / 27卷 / 5期
关键词
Breast cancer; Ductal carcinoma in situ (DCIS); Microinvasion; Pseudoinvasion;
D O I
10.1007/s00292-006-0853-y
中图分类号
学科分类号
摘要
Ductal carcinoma in situ (DCIS) is a heterogeneous disease that progresses to invasive cancer in 30-50% of the patients. Its natural history is poorly defined so that we are unable to identify cases of DCIS that do not progress to invasive carcinoma during an individual's lifetime. However, pathologic features of DCIS are nowadays the basis for the estimation of the prognosis and planning of therapy. Exclusion of microinvasion, characterization of nuclear grade, architecture, size and distribution of the DCIS, presence or absence of comedonecrosis as well as the assessment of surgical margins are relevant factors for local treatment. The determination of steroid hormone receptor status is indicated in patients considering tamoxifen therapy after breast conservation. It is advisable to evaluate the features according to internationally accepted guidelines with proven prognostic relevance and reproducibility. Nevertheless, better prognostic factors are needed to adapt the management of this increasingly diagnosed disease to the individual patient. © Springer Medizin Verlag 2006.
引用
收藏
页码:326 / 336
页数:10
相关论文
共 31 条
[1]  
Badve S., A'Hern R.P., Ward A.M., Et al., Prediction of local recurrence of ductal carcinoma in situ of the breast using five histological classifications: A comparative study with long follow-up, Hum Pathol, 29, pp. 915-923, (1998)
[2]  
Bassler R., Mamma, Pathologie, 4, (1997)
[3]  
Bijker N., Peterse J.L., Duchateau L., Et al., Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: Analysis of European Organization for Research and Treatment of Cancer Trial 10853, J Clin Oncol, 19, pp. 2263-2271, (2001)
[4]  
Blamey R.W., Macmillan R.D., Rampaul R.S., Et al., Ductal carcinoma in situ: Experience at Nottingham City Hospital 1973 through 2000, Ductal Carcinoma in Situ of the Breast, pp. 322-328, (2002)
[5]  
Consensus Conference on the classification of ductal carcinoma in situ, Cancer, 80, pp. 1798-1802, (1997)
[6]  
Quality assurance guidelines for pathology in mammography screening - Non-operative diagnosis, European Guidelines for Quality Assurance in Mammography Screening, pp. 159-172, (2001)
[7]  
Elston C.W., Ellis I.O., Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up, Histopathology, 19, pp. 403-410, (1991)
[8]  
Fisher E.R., Dignam J., Tan-Chiu E., Et al., Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: Intraductal carcinoma, Cancer, 86, pp. 429-438, (1999)
[9]  
Frykberg E.R., Bland K.I., Overview of the biology and management of ductal carcinoma in situ of the breast, Cancer, 74, pp. 350-361, (1994)
[10]  
Kreienberg R., Kopp I., Lorenz W., Et al., Interdisziplinäre S3-Leitlinie für Die Diagnostik und Therapie des Mammakarzinoms der Frau, (2004)